Herpes zoster is associated with an increased risk of subsequent lymphoid malignancies - A nationwide population-based matched-control study in Taiwan

BMC Cancer

Sheng-Fung Lin⁵  Pi-Yu Chang¹  Jui-Feng Hsu¹  Pai-Mei Lin⁶  Ming-Yu Yang²  Chao-Sung Chang⁵  Ta-Chih Liu⁴  Wen-Chi Yang¹  Hui-Hua Hsiao⁴  Yi-Hsin Yang³  Yi-Chang Liu⁴ 

[1]Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, 100, Tzyou 1st Road, Kaohsiung 807, Taiwan

[2]Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Wen-Hwa 1st Road, Kwei-Shan, Tao-Yuan, 333, Taiwan

[3]Statistical Analysis Laboratory, Department of Medical Research, Kaohsiung Medical University Hospital, 100, Tzyou 1st Road, Kaohsiung, 807, Taiwan

[4]Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, 100, Tzyou 1st Road, Kaohsiung, 807, Taiwan

[5]Department of Internal Medicine, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, 100, Tzyou 1st Road, Kaohsiung 807, Taiwan

[6]Department of Nursing, I-Shou University, 1 ,Sec. 1, Syuecheng Road., Dashu District, Kaohsiung, 840, Taiwan

关键词: Taiwan;    Epidemiology;    Leukemia;    Lymphoma;    Herpes zoster;   

Others  :  1080107
DOI  :  10.1186/1471-2407-12-503

 received in 2012-07-04, accepted in 2012-10-28,  发布年份 2012

【 摘 要 】

Background

Infectious agents have been shown to contribute to the development of lymphoid malignancies. The different distribution of lymphoid malignancies in Asian and Western populations suggests possibly different etiologies in Asian populations. Herpes zoster infection, commonly seen in immunocompromised persons, has been reported to be associated with lymphoid malignancies in retrospective case–control studies from Western populations, but the results are controversial and large-scale prospective studies from Asian populations are lacking.

Methods

A nationwide population-based matched-controlled prospective study on Taiwanese patients was performed using the National Health Insurance Research Database from 1996 to 2007. Herpes zoster and malignancies were defined by compatible ICD-9-CM (International Classification of Disease, 9^th Revision, Clinical Modification) codes. Patients who had been diagnosed with any malignancies before herpes zoster, with known viral infections including human immunodeficiency virus, and duration from herpes zoster to diagnosis of malignancies less than 6 months were excluded.

Results

Of 42,498 patients with herpes zoster prior to the diagnosis of any malignancies, the cumulative incidence for lymphoid malignancies was 0.11% (n = 48), compared with 0.06% (n = 106) in 169,983 age- and gender-matched controls (univariate hazard ratio (HR): 1.82, 95%CI: 1.29-2.55). The most common lymphoid malignancy was non-Hodgkin’s lymphoma (60.4%, n = 29), followed by multiple myeloma (27.1%, n = 13). Risk for developing lymphoid malignancies is significantly higher in herpes zoster patients (log rank P = 0.005). After adjusting for presence of any comorbidities in Charlson comorbidity index, time-dependent covariate for herpes group, and income category using Cox proportional hazard regressions, herpes zoster patients had an increased risk of developing lymphoid malignancies (adjusted HR: 1.68, 95%CI: 1.35-2.42, P = 0.0026), but did not have an increased risk of developing non-lymphoid malignancies (adjusted HR: 1.00, 95%CI: 0.91-1.05, P = 0.872).

Conclusion

Preceding herpes zoster infection is an independent risk marker for subsequent lymphoid malignancies in Taiwanese subjects. Further studies are warranted for pathogenesis exploration and preventive strategies in Asian populations.

【 授权许可】

   
2012 Liu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW: WHO classification of tumours of hematopoietic and lymphoid tissues. Lyon: IARC; 2008.
• [2]Dal Maso L, Franceschi S: Epidemiology of non-Hodgkin lymphomas and other haemolymphopoietic neoplasms in people with AIDS. Lancet Oncol 2003, 4:110-119.
• [3]Alexander DD, Mink PJ, Adami HO, Chang ET, Cole P, Mandel JS, Trichopoulos D: The non- Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer 2007, 120(Suppl 12):1-39.
• [4]Dave SS: Host factors for risk and survival in lymphoma. Hematology Am Soc Hematol Educ Program 2010, 2010:255-258.
• [5]Jarrett RF: Viruses and lymphoma/leukaemia. J Pathol 2006, 208(2):176-186.
• [6]Engels EA: Infectious agents as causes of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 2007, 16(3):401-404.
• [7]Ferreri AJ, Ernberg I, Copie-Bergman C: Infectious agents and lymphoma development: molecular and clinical aspects. J Intern Med 2009, 265(4):421-438.
• [8]Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD: Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol 2010, 48(Suppl 1):S2-S7.
• [9]Thomas SL, Hall AJ: What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 2004, 4(1):26-33.
• [10]Burke BL, Steele RW, Beard OW, Wood JS, Cain TD, Marmer DJ: Immune responses to varicella-zoster in the aged. Arch Intern Med 1982, 142:291-293.
• [11]Ragozzino MW, Melton LJ 3rd, Kurland LT, Chu CP, Perry HO: Risk of cancer after herpes zoster: a population-based study. N Engl J Med 1982, 307(7):393-397.
• [12]Smith JB, Fenske NA: Herpes zoster and internal malignancy. South Med J 1995, 88(11):1089-1092.
• [13]Landgren O, Gridley G, Check D, Caporaso NE, Morris Brown L: Acquired immune-related and inflammatory conditions and subsequent chronic lymphocytic leukaemia. Br J Haematol 2007, 139(5):791-798.
• [14]Anderson LA, Landgren O, Engels EA: Common community acquired infections and subsequent risk of chronic lymphocytic leukaemia. Br J Haematol 2009, 147(4):444-449.
• [15]Gramenzi A, Buttino I, D’Avanzo B, Negri E, Franceschi S, La Vecchia C: Medical history and the risk of multiple myeloma. Br J Cancer 1991, 63:769-772.
• [16]Brown LM, Gridley G, Check D, Landgren O: Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 2008, 111(7):3388-3394.
• [17]Kristinsson SY, Koshiol J, Björkholm M, Goldin LR, McMaster ML, Turesson I, Landgren O: Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia. J Natl Cancer Inst 2010, 102(8):557-567.
• [18]Müller AM, Ihorst G, Mertelsmann R, Engelhardt M: Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol 2005, 84(1):1-12.
• [19]Chen WL, Tsai WC, Chao TY, Sheu LF, Chou JM, Kao WY, Chen YC, Ho CL: The clinicopathological analysis of 303 cases with malignant lymphoma classified according to the World Health Organization classification system in a single institute of Taiwan. Ann Hematol 2010, 89(6):553-562.
• [20]The world health organization classification of malignant lymphomas in japan: incidence of recently recognized entities: Lymphoma Study Group of Japanese Pathologists. Pathol Int 2000, 50(9):696-702.
• [21]Han X, Kilfoy B, Zheng T, Holford TR, Zhu C, Zhu Y, Zhang Y: Lymphoma survival patterns by WHO subtype in the United States, 1973–2003. Cancer Causes Control 2008, 19(8):841-858.
• [22]Sukpanichnant S: Analysis of 1983 cases of malignant lymphoma in Thailand according to the World Health Organization classification. Hum Pathol 2004, 35(2):224-230.
• [23]Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992, 45(6):613-619.
• [24]Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
• [25]Charlson M, Szatrowski TP, Peterson J, Gold J: Validation of a combined comorbidity index. J Clin Epidemiol 1994, 47:1245-1251.
• [26]Tavani A, La Vecchia C, Franceschi S, Serraino D, Carbone A: Medical history and risk of Hodgkin's and non-Hodgkin's lymphomas. Eur J Cancer Prev 2000, 9(1):59-64.
• [27]Zintzaras E, Voulgarelis M, Moutsopoulos HM: The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005, 165:2337-2344.
• [28]Engels EA, Cerhan JR, Linet MS, Cozen W, Colt JS, Davis S, Gridley G, Severson RK, Hartge P: Immune-related conditions and immune-modulating medications as risk factors for non-Hodgkin’s lymphoma: a case–control study. Am J Epidemiol 2005, 162:1153-1161.
• [29]Smedby KE, Hjalgrim H, Askling J, Chang ET, Gregersen H, Porwit-MacDonald A, Sundström C, Akerman M, Melbye M, Glimelius B, Adami HO: Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 2006, 98:51-60.
• [30]Jih JS, Chen YJ, Lin MW, Chen YC, Chen TJ, Huang YL, Chen CC, Lee DD, Chang YT, Wang WJ, Liu HN: Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006. Acta Derm Venereol 2009, 89(6):612-616.
• [31]Lin YH, Huang LM, Chang IS, Tsai FY, Lu CY, Shao PL, Chang LY: Disease burden and epidemiology of herpes zoster in pre-vaccine Taiwan. Vaccine 2010, 28(5):1217-1220.
• [32]Chen CJ, You SL, Pan WH: Seroepidemiology of Epstein-Barr virus and cytomegalovirus infection among preschool and school children in Taiwan. Chin J Microbiol Immunol 1991, 24:150-158.